China National Drug Administration grants rapid approval of Roche ’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Roche today announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa ® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | China Health | Grants | Lung Cancer | Lymphoma | Marketing | Non-Small Cell Lung Cancer | Pharmaceuticals